LCTX Files 8-K Furnishing Press Release on Q2 2025 Results

Rhea-AI Filing Summary

On August 12, 2025, Lineage Cell Therapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025, which is provided as Exhibit 99.1. The Form 8-K states the information is being furnished, not filed, and therefore is not incorporated by reference into other filings. The filing also includes an Inline XBRL cover page as Exhibit 104. The report is signed by George A. Samuel III, General Counsel and Corporate Secretary.

Insights

Securities Analyst

TL;DR Routine 8-K furnishing Q2 results; substantive figures reside in the press release, not the form—limited immediate impact.

The filing notifies investors that a press release reporting financial results for the quarter ended June 30, 2025 was furnished as Exhibit 99.1. This Form 8-K does not itself contain financial figures or analysis; it functions as a procedural disclosure that points investors to the press release. Because the information is expressly "furnished, not filed," it is not incorporated by reference into other filings. Review of Exhibit 99.1 is required to assess revenue, earnings, cash position, or other material financial metrics.

Corporate Governance Expert

TL;DR The 8-K follows standard disclosure practice, clarifying furnished status and including the required exhibits and signature.

This submission reflects routine compliance: it lists Exhibits 99.1 (press release) and 104 (Inline XBRL cover page), and includes the registrant's signature by the General Counsel and Corporate Secretary. The explicit statement that the information is furnished and not incorporated by reference is a legal distinction that limits automatic reuse of the press release content in future filings. There are no governance red flags or executive changes disclosed in this document.

0000876343false00008763432025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Lineage Cell Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

California			001-12830	94-3127919
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2173 Salk Avenue, Suite 200
Carlsbad, California				92008
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (442) 287-8990

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common shares		LCTX		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter ended June 30, 2025, a copy of which is furnished as Exhibit 99.1.

The information under this Item 2.02 and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release issued August 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Lineage Cell Therapeutics, Inc.
Date:	August 12, 2025	By:	/s/ George A. Samuel III
		Name: Title:	George A. Samuel III General Counsel and Corporate Secretary

FAQ

What did Lineage Cell Therapeutics (LCTX) report in this 8-K?

The company furnished a press release announcing financial results for the quarter ended June 30, 2025, provided as Exhibit 99.1 to the Form 8-K dated August 12, 2025.

Where can I find the financial details for LCTX's quarter ended June 30, 2025?

See Exhibit 99.1 (the press release) furnished with this 8-K; the 8-K itself does not include the detailed financial figures.

Is the press release incorporated by reference into other filings?

No. The Form 8-K expressly states the information is being furnished and is not being filed for purposes of Section 18 and is not incorporated by reference into other filings.

What exhibits were included with this Form 8-K?

Exhibit 99.1 (press release issued August 12, 2025) and Exhibit 104 (Cover Page Interactive Data File/Inline XBRL).

When was this Form 8-K filed?

The report date is August 12, 2025.

What is Lineage Cell Therapeutics' trading symbol and exchange?

LCTX on the NYSE American exchange.